A robust immunohistochemical (IHC) assay for VEGFR2 was developed to investigate its utility for patient tailoring in clinical trials. The sensitivity, specificity, and selectivity of the IHC assay we
Scores in the table are summarized by the median values. *: scored out of 10. Significant: the P-value for the statistical test comparing survival distributions between the groups with and without EGF